DE60033633D1 - Kit aus polyakrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und der diabetes mellitus - Google Patents

Kit aus polyakrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und der diabetes mellitus

Info

Publication number
DE60033633D1
DE60033633D1 DE60033633T DE60033633T DE60033633D1 DE 60033633 D1 DE60033633 D1 DE 60033633D1 DE 60033633 T DE60033633 T DE 60033633T DE 60033633 T DE60033633 T DE 60033633T DE 60033633 D1 DE60033633 D1 DE 60033633D1
Authority
DE
Germany
Prior art keywords
animal
capsule
tissue
diabetes mellitus
polyacrylamidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60033633T
Other languages
English (en)
Other versions
DE60033633T2 (de
Inventor
Dmitry Vladimirovich Zybin
Alexei Gennadievich Kotelevits
Sergei Evgenievich Severin
Vladimir Konstantinovi Sologub
Ljubov Leonidovna Mironova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERCELL BIOTECHNOLOGY BV
Original Assignee
VERCELL BIOTECHNOLOGY BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU99125349A external-priority patent/RU2152800C1/ru
Priority claimed from RU2000116208A external-priority patent/RU2165263C1/ru
Application filed by VERCELL BIOTECHNOLOGY BV filed Critical VERCELL BIOTECHNOLOGY BV
Publication of DE60033633D1 publication Critical patent/DE60033633D1/de
Application granted granted Critical
Publication of DE60033633T2 publication Critical patent/DE60033633T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/243—Cells of the female genital tract, non-germinal ovarian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60033633T 1999-12-08 2000-11-22 Kit aus polyacrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und diabetes mellitus Expired - Fee Related DE60033633T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU99125349 1999-12-08
RU99125349A RU2152800C1 (ru) 1999-12-08 1999-12-08 Способ культивирования и модификации гетерогенных клеток млекопитающих
RU2000116208 2000-06-23
RU2000116208A RU2165263C1 (ru) 2000-06-23 2000-06-23 Способ лечения сахарного диабета
PCT/RU2000/000477 WO2001041809A1 (fr) 1999-12-08 2000-11-22 Utilisation d'un gel polyacrilamide pour former une capsule dans un tissu d'un mammalien, procede de culture de cellules et procede de traitement des maladies oncologiques et du diabete sucre

Publications (2)

Publication Number Publication Date
DE60033633D1 true DE60033633D1 (de) 2007-04-12
DE60033633T2 DE60033633T2 (de) 2007-11-15

Family

ID=26654029

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033633T Expired - Fee Related DE60033633T2 (de) 1999-12-08 2000-11-22 Kit aus polyacrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und diabetes mellitus

Country Status (9)

Country Link
US (1) US6972194B1 (de)
EP (1) EP1151756B1 (de)
JP (1) JP2003516364A (de)
KR (1) KR20010093331A (de)
CN (1) CN100408098C (de)
AT (1) ATE355083T1 (de)
CA (1) CA2361563A1 (de)
DE (1) DE60033633T2 (de)
WO (1) WO2001041809A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2165263C1 (ru) * 2000-06-23 2001-04-20 Зыбин Дмитрий Владимирович Способ лечения сахарного диабета
ATE357259T1 (de) * 2002-04-10 2007-04-15 Obschestvo S Ogranichennoy Otv Polyfunktionales biokompatibles hydrogel und verfahren zu seiner herstellung
US10918707B2 (en) * 2015-06-16 2021-02-16 University Of Florida Research Foundation, Incorporated VirB10 for vaccination against gram negative bacteria

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050012A1 (de) * 1979-11-06 1982-05-06 I Bilko Polyacrylamide gel for medical and biological application and method of its preparation
SU977466A1 (ru) * 1979-11-06 1982-11-30 Киевский Ордена Трудового Красного Знамени Медицинский Институт Им.Акад.А.А.Богомольца Полиакриламидный гель дл медико-биологических целей и способ его получени
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO158284C (no) * 1981-03-13 1988-08-17 Damon Biotech Inc Fremgangsmaate for selektiv oppbrytning av en permeabel membran.
JPH03266980A (ja) * 1989-03-16 1991-11-27 W R Grace & Co 細胞培養用基材およびそれを用いた細胞集合体の製造方法
JPH0382472A (ja) * 1989-08-28 1991-04-08 Terumo Corp 生体内長期埋植材及びその製造方法
JP3035719B2 (ja) 1991-06-27 2000-04-24 日本バイリーン株式会社 多孔質シートの製造方法
RU2026643C1 (ru) 1992-12-25 1995-01-20 Зыбин Дмитрий Владимирович Способ лечения больных с нарушением мужской половой функции методом трансплантации
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
RU2090185C1 (ru) 1994-09-30 1997-09-20 Минаев Б.Д. Микрокапсула
US5827707A (en) * 1995-06-07 1998-10-27 Neocrin Company Method for manufacturing minimal volume capsules containing biological materials
GB9516556D0 (en) * 1995-08-12 1995-10-11 Smith & Nephew Cell culture laminate
BG102375A (en) * 1997-08-26 1999-11-30 Пегас Оод Inoculation biocompatible hydrophilic gel, method for its preparation and application
RU2135193C1 (ru) 1997-10-28 1999-08-27 Скалецкий Николай Николаевич Способ получения материала, содержащего бета-клетки поджелудочной железы, для трансплантации больным сахарным диабетом с использованием феномена миграции клеток, материал, содержащий бета-клетки поджелудочной железы, для трансплантации больным сахарным диабетом и способ лечения сахарного диабета методом его трансплантации
WO1999052356A1 (en) * 1998-04-09 1999-10-21 Charlotte-Mecklenberg Hospital Authority Creation of three-dimensional tissues
EP1173517A4 (de) * 1999-04-26 2006-06-28 California Inst Of Techn Hydrogele die sich in situ formen

Also Published As

Publication number Publication date
CA2361563A1 (en) 2001-06-14
JP2003516364A (ja) 2003-05-13
WO2001041809A1 (fr) 2001-06-14
DE60033633T2 (de) 2007-11-15
KR20010093331A (ko) 2001-10-27
EP1151756A4 (de) 2004-05-12
US6972194B1 (en) 2005-12-06
EP1151756A1 (de) 2001-11-07
EP1151756B1 (de) 2007-02-28
ATE355083T1 (de) 2006-03-15
CN100408098C (zh) 2008-08-06
CN1339971A (zh) 2002-03-13

Similar Documents

Publication Publication Date Title
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE110255T1 (de) Gebrauch von ghl-cu derivaten für die herstellung eines medikaments zur stimulierung des haarwachstums.
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
WO2005072764A3 (en) Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
ATE220913T1 (de) Neues physiologisch aktives mittel
ZA200900444B (en) Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
WO2004011631A3 (en) Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60033633D1 (de) Kit aus polyakrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und der diabetes mellitus
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
Hou et al. Effects of Bleaching Associated with Er: YAG and Nd: YAG Laser on Enamel Structure and Bacterial Biofilm Formation
RU2240809C1 (ru) Способ получения бесклеточного дермального матрикса
CN107029221A (zh) 胱氨酸蛋白酶抑制剂在制备防治紫外光诱导的皮肤损伤药物、保健品及各种制剂中的应用
WO2021059986A1 (ja) コラーゲン産生亢進剤、医薬品、化粧品、及びコラーゲン産生亢進剤の製造方法
CN209360953U (zh) 一种活动义齿
RU2003116380A (ru) Способ лечения глубокого кариеса
JP2006036742A (ja) 水虫薬・土槿皮（どきんぴ）エキス溶液と治療法と用具。
NZ512256A (en) Polyacrylamide gel injected in vivo into the tissue forming capsules wherein desired cells (such as beta-islet pancreatic cells) are injected into and cultivated for treating oncological diseases and diabetes mellitus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee